Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX + Anlotinib + Sintilimab in Pancreatic Cancer
NCT06761027Phase 2Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and sintilimab in pancreatic cancer (PC), sponsored by Fujian Provincial Hospital. Primary endpoint: Objective Response Rate. Started Dec 2024; status: recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06761027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761027.